Invasive Fungal Infections Market Report 2026

Invasive Fungal Infections Market Overview

• Invasive Fungal Infections market size has reached to $7.91 billion in 2025 • Expected to grow to $10.1 billion in 2030 at a compound annual growth rate (CAGR) of 5.2% • Growth Driver: Impact Of HIV Epidemic On The Invasive Fungal Infection Market • Market Trend: Advancements Launch of Zisavel Capsules for Fungal Infections • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Invasive Fungal Infections Market?

Invasive fungal infections refer to severe diseases caused by pathogenic fungi that penetrate and spread within the body beyond the point of initial infection. These infections are characterized by the penetration of fungal organisms into deeper layers of tissue, such as the bloodstream, organs, or other body structures. Invasive fungal infection treatment typically includes using antifungal medications and surgical procedures to excise infected tissue in certain instances. The main types of invasive fungal infections are candidemia and invasive candidiasis, intraabdominal candidiasis, cryptococcal meningitis, esophageal candidiasis, histoplasmosis acute pulmonary, and others. Candidemia and invasive candidiasis are infections caused by candida fungus that affect the blood, heart, brain, eyes, bones, or other parts of the body. These are treated with drug types such as polyenes, triazoles, echinocandins, flucytosine, and others by end users such as hospitals, homecare, specialty clinics, and others.

What Is The Invasive Fungal Infections Market Growth Forecast?

The invasive fungal infections market size is expected to see strong growth in the next few years. It will grow to $10.1 billion in 2030 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to development of novel antifungal drug classes, increasing awareness of antifungal resistance, expansion of critical care infrastructure, improved diagnostic capabilities for fungal infections, growing investment in infectious disease research. Major trends in the forecast period include rising incidence of invasive fungal infections in immunocompromised patients, increasing adoption of echinocandins as first-line therapy, growing use of combination antifungal treatment strategies, expansion of hospital-based antifungal stewardship programs, rising demand for broad-spectrum and targeted antifungal agents.

Global Invasive Fungal Infections Market Segmentation

1) By Disease Type: Candidemia And Invasive Candidiasis, Intra Abdominal Candidiasis, Cryptococcal Meningitis, Esophageal Candidiasis, Histoplasmosis Acute Pulmonary, Other Disease Types 2) By Drug Type: Polyenes, Triazoles, Echinocandins, Flucytosine, Other Drug Types 3) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End-Users Subsegments: 1) By Candidemia And Invasive Candidiasis: Bloodstream Infections, Disseminated Candidiasis 2) By Intra-Abdominal Candidiasis: Peritoneal Candidiasis, Abscess Formation 3) By Cryptococcal Meningitis: Primary Cryptococcal Meningitis, Secondary Cryptococcal Meningitis 4) By Esophageal Candidiasis: Acute Esophageal Candidiasis, Chronic Esophageal Candidiasis 5) By Histoplasmosis Acute Pulmonary: Disseminated Histoplasmosis, Chronic Pulmonary Histoplasmosis 6) By Other Disease Types: Aspergillosis, Mucormycosis, Other Rare Fungal Infections

What Is The Driver Of The Invasive Fungal Infections Market?

The rise in the population suffering from human immunodeficiency virus (HIV) is expected to propel the growth of the invasive fungal infection market going forward. HIV (Human Immunodeficiency Virus) infection is a virus that compromises the immune system's ability to defend against diseases and illnesses. The rising number of individuals with compromised immune systems, such as HIV (Human Immunodeficiency Virus) or AIDS (acquired immunodeficiency syndrome), increases the susceptibility to invasive fungal infections, creating opportunities for manufacturers to develop and supply specialized and more effective antifungal drugs. For instance, in July 2025, according to the Joint United Nations Programme on HIV/AIDS (UNAIDS), a Switzerland-based international organization, 40.8 million [37.0 million–45.6 million] people were living with HIV in 2024. That same year, an estimated 1.3 million [1 million–1.7 million] individuals acquired new HIV infections, while 630 000 [490 000–820 000] people lost their lives to AIDS-related illnesses. Therefore, the rise in the population suffering from the human immunodeficiency virus (HIV) will drive the growth of the invasive fungal infection industry.

Key Players In The Global Invasive Fungal Infections Market

Major companies operating in the invasive fungal infections market are Pfizer Inc., Merck And Co. Inc., Bayer AG, Abbott Laboratories, GSK plc, Gilead Sciences Inc., Mylan N.V., Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., BioMarin Pharmaceutical Inc., Xellia Pharmaceuticals, Basilea Pharmaceutica, Cidara Therapeutic Inc., Pulmocide Ltd., NovaBiotics Ltd, F2G Ltd., Giner Inc., Ciron Drugs And Pharmaceuticals Pvt. Ltd., Hexima Limited, Scynexis Inc., Enzon Pharmaceuticals Inc., Matinas BioPharma Holdings Inc., Biosergen AB

Global Invasive Fungal Infections Market Trends and Insights

Major companies operating in the invasive fungal infection market are focused on innovative products such as Zisavel capsules to enhance treatment efficacy, improve patient outcomes, and increase accessibility for those affected by serious fungal infections. Zisavel capsules are a generic antifungal medication derived from isavuconazole, designed to treat invasive aspergillosis and mucormycosis. These 100 mg capsules aim to provide an affordable alternative for patients, enhancing access to effective treatment. For instance, in October 2023, BDR Pharmaceuticals, an India-based generic and specialty pharmaceutical company, launched a generic antifungal drug, Zisavel Capsules, to treat invasive aspergillosis and mucormycosis. Zisavel is indicated for the treatment of invasive aspergillosis and mucormycosis, both of which are severe fungal infections that can be life-threatening. The introduction of Zisavel aims to make treatment more accessible to patients by significantly lowering costs compared to current options like voriconazole and posaconazole.

What Are Latest Mergers And Acquisitions In The Invasive Fungal Infections Market?

In August 2023, Sandoz, a Germany-based pharmaceutical company that specializes in generic medicines and biosimilars, acquired Astellas Pharma Inc. for an undisclosed amount. With this acquisition, Sandoz aims to enhance its portfolio of generic and biosimilar products, expand its market presence, and leverage synergies to drive growth and innovation in the pharmaceutical sector. Astellas Pharma Inc. is a Japan-based pharmaceutical company that focuses on research, development, manufacturing, and marketing of innovative medications.

Regional Outlook

North America was the largest region in the invasive fungal infections market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Invasive Fungal Infections Market?

The invasive fungal infections market consists of revenues earned by entities by providing services such as diagnostic testing, clinical research and development, educational programs, and awareness campaign services. The market value includes the value of related goods sold by the service provider or included within the service offering. The invasive fungal infections market also includes sales of azoles, allylamines, and morpholines, which are used in treating invasive fungal infections. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Invasive Fungal Infections Market Report 2026?

The invasive fungal infections market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the invasive fungal infections industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.